JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.

导出 OA

翻译打印收藏纠错

作者： Mark D,Russell ^[1] ; Christopher,Stovin ^[2] ; Edward,Alveyn ^[2] ; Olukemi,Adeyemi ^[2] ; Chun Kit David,Chan ^[2] ; Vishit,Patel ^[2] ; Maryam A,Adas ^[2] ; Fabiola,Atzeni ^[3] ; Kenrick K H,Ng ^[4] ; Andrew I,Rutherford ^[2] ; Sam,Norton ^[2] ; Andrew P,Cope ^[2] ; James B,Galloway ^[2]

作者单位： Centre for Rheumatic Diseases, King's College London, London, UK mark.russell@kcl.ac.uk. ^[1] Centre for Rheumatic Diseases, King's College London, London, UK. ^[2] Rheumatology Unit, University of Messina, Messina, Italy. ^[3] Department of Medical Oncology, University College London, London, UK. ^[4]

关键词 arthritis, psoriatic arthritis, rheumatoid biological therapy epidemiology spondylitis, ankylosing

主题词成年人(Adult);人类(Humans);甲氨蝶呤(Methotrexate);抗风湿药(Antirheumatic Agents);关节炎, 类风湿(Arthritis, Rheumatoid);肿瘤(Neoplasms)

DOI 10.1136/ard-2023-224049

PMID 37247942

发布时间 2023-11-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交